Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Health experts are warning of a potential 'tripledemic' this winter - here's how to spot the early symptoms of flu, RSV and ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

The NHS has listed the symptoms of covid, RSV and flu to help you tell the difference between each one, as cases forecast to ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

The NHS has listed the symptoms of covid, RSV and flu to help you tell the difference between each one, as cases forecast to surge ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

RSV, or Respiratory Syncytial Virus, is a highly contagious virus that frequently spreads among preschool children, ...